22260-51-1
2-bromo-alpha-ergocryptine methane-sulfonate
CAS: 22260-51-1
Molecular Formula: C33H44BrN5O8S
22260-51-1 - Names and Identifiers
| Name | 2-bromo-alpha-ergocryptine methane-sulfonate |
| Synonyms | BRC BCT Bromocriptine Mesylate BROMOCRIPTINE MESYLATE (+)-BROMOCRIPTINE MESYLATE BROMOCRIPTINE METHANESULPHONATE (+)-BROMOCRIPTINE METHANESULFONATE 2-bromo-alpha-ergocryptine methane-sulfonate BROMOCRYPTINE MESYLATE METHANESULFONATE SALT 2-bromo-A-ergocryptine methanesulfonate salt (5'A)-2-BROMO-12'-HYDROXY-2'-(1-METHYLETHYL)-5'-(2-METHYLPROPYL)ERGOTAMAN-3',6',18-TRIONE MESYLATE (8xi,12'xi)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman methanesulfonate (salt) (5xi,5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman methanesulfonate (salt) |
| CAS | 22260-51-1 |
| EINECS | 244-881-1 |
| InChI | InChI=1/C32H40BrN5O5.CH4O3S/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18;1-5(2,3)4/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39);1H3,(H,2,3,4)/t18?,23-,24?,25+,31-,32?;/m1./s1 |
| InChIKey | NOJMTMIRQRDZMT-JGYCFGIMSA-N |
22260-51-1 - Physico-chemical Properties
| Molecular Formula | C33H44BrN5O8S |
| Molar Mass | 750.7 |
| Melting Point | 192-196° (dec) |
| Boling Point | 992.4°C at 760 mmHg |
| Specific Rotation(α) | D20 +95° (c = 1 in methanol-methylene chloride) |
| Flash Point | 554°C |
| Solubility | H2O: 0.8mg/mL |
| Vapor Presure | 0mmHg at 25°C |
| Appearance | solid |
| Color | white |
| Merck | 13,1400 |
| BRN | 4115238 |
| pKa | 4.90(at 25℃) |
| Storage Condition | 2-8°C |
| Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months |
| In vitro study | Bromocriptine stimulates [ 35 S]-GTPγS binding at D2 dopamine receptor expressed in CHO cells with pEC 50 of 8.15±0.05. Bromocriptine also is a strong inhibitor of brain nitric oxide synthase. The ergot alkaloid Bromocriptine (BKT) is found to act as a strong inhibitor of purified neuronal nitric oxide synthase (NOS) (IC 50 =10±2 μM) whereas it is poorly active towards inducible macrophage NOS (IC 50 >100 μM) . Bromocriptine is found to inhibit the activity of at least one human cytochrome P450 enzyme. Bromocriptine is a potent inhibitor of CYP3A4 with a calculated IC 50 value for the interaction of 1.69 μM. |
| In vivo study | Bromocriptine mesylate (2 mg/kg, i.p.) is administered for 7 days in groups of mice in forced swimming test (FST) and tail suspension test (TST). Bromocriptine group shows significant anti-immobility action as compared to control. When Bromocriptine administered 30 min after the last dose of 7 days MPE treatment and subjected to FST, this dopaminergic agonist produces significant and dose dependent potentiation of anti-immobility action of MPE (200 mg/kg, p.o.) as compared to MPE treatment alone. Bromocriptine treatment group shows a significant reduction of immobility time as compared to control. Bromocriptine administration after 7 days pretreatment with MPE (100 and 200 mg/kg, p.o.) shows significant and dose dependent potentiation of anti-immobility action of MPE as compared to MPE treatment alone. Intracisternal administration of Bromocriptine decreases significantly the static mechanical allodynia (SMA) score compared to that of sham (saline-injected rats) and its effect lasted for 30 min. Intraperitoneal administration of Bromocriptine induces a significant, dose dependent (0.1 mg and 1 mg/kg) decrease in pain scores in CCI-IoN group when compared to sham and its effect lasted for 6 h. The highest dose induces the highest score decrease (P<0.01). Bromocriptine effect lasts for 20 min. Intraperitoneal administration of Bromocriptine induces a significant dose dependent decrease in SMA score in CCI-IoN+6-OHDA lesioned group compared to that of sham. Its effect lasts for 6 h. |
22260-51-1 - Risk and Safety
| Hazard Symbols | Xn - Harmful |
| Risk Codes | 20/21/22 - Harmful by inhalation, in contact with skin and if swallowed. |
| Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36 - Wear suitable protective clothing. |
| UN IDs | UN 3077 9 / PGIII |
| WGK Germany | 3 |
| RTECS | KE1595000 |
| FLUKA BRAND F CODES | 3-10 |
| HS Code | 29396900 |
| Toxicity | LD50 in mice, rats, rabbits (mg/kg): 190, 72, 12.5 i.v. (Parkes) |
22260-51-1 - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 1.332 ml | 6.66 ml | 13.321 ml |
| 5 mM | 0.266 ml | 1.332 ml | 2.664 ml |
| 10 mM | 0.133 ml | 0.666 ml | 1.332 ml |
| 5 mM | 0.027 ml | 0.133 ml | 0.266 ml |
Last Update：2024-01-02 23:10:35
Supplier List
Spot supply
Product Name: Bromocriptine Mesylate Visit Supplier Webpage Request for quotationCAS: 22260-51-1
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Spot supply
Product Name: Bromocriptine mesylate Visit Supplier Webpage Request for quotationCAS: 22260-51-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Bromocriptine Mesylate Visit Supplier Webpage Request for quotationCAS: 22260-51-1
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Spot supply
Product Name: Bromocriptine mesylate Visit Supplier Webpage Request for quotationCAS: 22260-51-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History